NCT02576977 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 126
- group Id
- BG001
- value
- 125
- group Id
- BG002
- value
- 251
- units
- Participants
- groups
- description
- Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
- id
- BG000
- title
- Pembrolizumab+Pomalidomide+Dexamethasone
- description
- Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
- id
- BG001
- title
- Standard of Care (SOC) Pomalidomide+Dexamethasone
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.3
- value
- 65.5
- group Id
- BG001
- spread
- 10.0
- value
- 66.4
- group Id
- BG002
- spread
- 9.6
- value
- 65.9
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 48
- group Id
- BG001
- value
- 46
- group Id
- BG002
- value
- 94
- title
- Female
- measurements
- group Id
- BG000
- value
- 78
- group Id
- BG001
- value
- 79
- group Id
- BG002
- value
- 157
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 13
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 110
- group Id
- BG001
- value
- 117
- group Id
- BG002
- value
- 227
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 11
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 29
- title
- Asian
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 24
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 92
- group Id
- BG001
- value
- 95
- group Id
- BG002
- value
- 187
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 5
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 108
- group Id
- BG001
- value
- 108
- group Id
- BG002
- value
- 216
- title
- Refractory to Lenalidomide
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 35
- title
- Sensitive to Lenalidomide
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Disease Status (Refractory vs. Sensitive to Lenalidomide)
- unit Of Measure
- Participants
- population Description
- The analysis population included all randomized participants.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 126
- group Id
- BG001
- value
- 125
- group Id
- BG002
- value
- 251
- units
- Participants
- groups
- description
- Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
- id
- BG000
- title
- Pembrolizumab+Pomalidomide+Dexamethasone
- description
- Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
- id
- BG001
- title
- Standard of Care (SOC) Pomalidomide+Dexamethasone
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.3
- value
- 65.5
- group Id
- BG001
- spread
- 10.0
- value
- 66.4
- group Id
- BG002
- spread
- 9.6
- value
- 65.9
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 48
- group Id
- BG001
- value
- 46
- group Id
- BG002
- value
- 94
- title
- Female
- measurements
- group Id
- BG000
- value
- 78
- group Id
- BG001
- value
- 79
- group Id
- BG002
- value
- 157
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 13
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 110
- group Id
- BG001
- value
- 117
- group Id
- BG002
- value
- 227
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 11
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 29
- title
- Asian
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 24
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 92
- group Id
- BG001
- value
- 95
- group Id
- BG002
- value
- 187
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 5
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 108
- group Id
- BG001
- value
- 108
- group Id
- BG002
- value
- 216
- title
- Refractory to Lenalidomide
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 35
- title
- Sensitive to Lenalidomide
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Disease Status (Refractory vs. Sensitive to Lenalidomide)
- unit Of Measure
- Participants
- population Description
- The analysis population included all randomized participants.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle